Bookings Hit Four-Year High as Biotech Demand Returns, Shares Surge 11%
CRL sits 80% above its 52-week low of $144.26.
Summary
Charles River's Q2 bookings jumped to $701 million, the highest in nearly four years, with a book-to-bill ratio of 1.19x — concrete evidence that biotech demand is rebounding. This follows the earlier Q2 beat and guidance raise reported today, but the bookings data and 11% stock surge to a new 52-week high add fresh conviction. The DSA backlog expanded to $1.97 billion, driven by IND-enabling studies and strong NHP demand, while RMS weakness from flat NIH budgets persists. The raised full-year guidance now calls for EPS of $11.15-$11.45 on revenue of $3.879-$3.920 billion, both above consensus.
At the time of this announcement, CRL was trading at $259.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $144.26 to $267.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.